Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Unresectable stage III non-small-cell lung cancer, drawn from the whole corpus: 14 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Pneumonitis from radiotherapy followed by immunotherapy limits treatment in patients with poor lung function.
Whether ALK, RET, ROS1 or other driver subtypes should receive targeted rather than immune consolidation is untested.
Patients too frail for concurrent chemoradiation, a large share, have no evidence-based route to durvalumab.
Proton therapy's heart-sparing has not yet been shown to improve survival.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
PFS HR 0.
Concurrent durvalumab with chemoradiotherapy did not significantly improve progression-free survival over chemoradiotherapy alone.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
OS HR 0.